John L. LubniewskiPresident & CEOMr. Lubniewski has served as our Chief Executive Officer and as a member of our Board of Directors since April 2019 and previously served as our President and Chief Operating Officer since April 2018. Prior to this he served as our Senior Vice President and Chief Business Officer since April 2011. Mr. Lubniewski joined us from Ventana, a medical diagnostics company and member of the Roche Group and global headquarters of Roche Tissue Diagnostics (“RTD”) where he served in leadership roles for nine years both before and after the acquisition of Ventana by Roche in March 2008. From August 2010 to April 2011, Mr. Lubniewski was Senior Vice President and Lifecycle Leader, Advanced Staining Platforms at Ventana. From January 2008 to August 2010, Mr. Lubniewski served as Senior Vice President and Lifecycle Leader, Clinical Assays at RTD, with responsibility for three lifecycle teams, technical marketing and medical marketing and global accountability for all RTD clinical assay products. Prior to the Roche acquisition of Ventana, Mr. Lubniewski served at Ventana as Senior Vice President, Advanced Staining Business Unit, Vice President Worldwide Marketing and Translational Diagnostic Business Unit, and General Manager, Research Products. In these roles, Mr. Lubniewski was responsible for a variety of assay and platform development and commercialization efforts. Prior to Ventana, Mr. Lubniewski worked for over ten years at Corning, Inc., a manufacturing company, in a variety of divisional, sector and corporate sales and marketing roles. Mr. Lubniewski earned a B.S. in Chemical Engineering from Clarkson University.
Shaun D. McMeansSenior Vice President of Finance, Administration and Chief Financial OfficerMr. McMeans has served as our Chief Financial Officer since February 2012, and as our Senior Vice President of Finance & Administration since February 2018. He previously was our Vice President of Finance & Administration from February 2012 until February 2018. Prior to joining us, Mr. McMeans was Vice President – Finance of Securaplane Technologies, Inc., a product supply company and division of Meggitt PLC, an aerospace, defense and energy conglomerate, from May 2011 to February 2012. Mr. McMeans was a financial consultant from February 2008 to April 2011, working both in an individual capacity and as a partner for Tatum LLC, a consulting company. Prior to February 2008, Mr. McMeans was Chief Financial Officer for The Long Companies, a full service residential and commercial real estate division of Berkshire Hathaway, Inc. Mr. McMeans also worked for over five years at LXU Healthcare, Inc., a manufacturer and distributor of specialty surgical equipment, as Controller and then Chief Financial and Operating Officer. In his early career, Mr. McMeans worked in roles of increasing responsibility, including Director of Finance, for Burnham Holdings, Inc., formerly Burnham Corporation, a manufacturer and distributor of residential and commercial hydronic heating equipment. Mr. McMeans received his B.S. in Accounting from The Pennsylvania State University.
Sam M. Rua Jr.Senior Vice President of Regulatory Affairs and Quality SystemsMr. Rua has served as our Senior Vice President of Regulatory Affairs and Quality Systems since February 2018. Previously he served as our Vice President of Regulatory Affairs and Quality Systems from November 2011 until February 2018. He directs the quality systems organization as well as global regulatory and clinical affairs. Prior to joining us, Mr. Rua served in a variety of quality and regulatory roles with increasing responsibilities, most recently with Ventana, a medical diagnostics company and member of the Roche Group and global headquarters of RTD, where he successfully led initiatives for PMA approvals and clearances for multiple IVD and companion diagnostic tests. Mr. Rua also was the Vice President of Global Regulatory and Clinical Affairs at Beckman Coulter from 2007 - 2010, and Executive Director of Quality and Regulatory at Third Wave Technologies, Inc. (now Hologic) from 2004-2007. While at Third Wave, he led the regulatory and clinical strategies for the Invader® UGT1A1 test and the Invader® HPV test. Mr. Rua received a B.S. in microbiology from the University of Arizona.